Long-term endocrine outcomes of transsphenoidal surgery for prolactinomas: a 20-year single-center cohort study
Authors' conclusion
In this highly selected surgical cohort, transsphenoidal surgery was followed by durable endocrine control in approximately half of the patients and by a low recurrence rate.
Study context
- Population
- Patients who underwent transsphenoidal surgery for prolactinomas at a tertiary referral center, September 1995–July 2015; 47 women and 8 men, median age 30 years; 35 microprolactinomas (64%), 18 macroprolactinomas (33%), 2 giant prolactinomas (3%)median follow-up 10.8 years
- Participants
- 55 patients
- Outcome
- Biochemical remission: normalization of serum prolactin
- Follow-up
- 6 months after surgery
Methodological detailssingle-centre, descriptive
- Single-centre
- Descriptive
Main finding
As reported in the abstract
Endocrine outcomes after transsphenoidal surgery · 6 months; long-term follow-up
Biochemical remission at 6 months
29 patients
53%
Persistent disease
21
38%
Recurrence
5 patients
9%
Observational data: associations, not effects.
Further findings
Remission by tumour size
- Remission rate, microprolactinomas
- 60%
- Remission rate, macroprolactinomas
- 44%
- Both giant prolactinomas had persistent disease
- Exploratory subgroup comparison
Remission by sex
- Remission in men
- 0 of 8
- Remission in women
- 29 of 47 women (62%)
- Men with macro- or giant prolactinoma
- 6 of the 8
- Median preoperative prolactin, men
- 848.7 ng/mL
- Median preoperative prolactin, women
- 136.4 ng/mL
- This observation is exploratory
Safety
- Transient diabetes insipidus
- 9%
- Permanent complications were uncommon
Original publication
Long-term endocrine outcomes of transsphenoidal surgery for prolactinomas: a 20-year single-center cohort study. Pituitary. Published 20 August 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →